Summary of Key Points
The Phase III clinical trial of the mRNA cancer vaccine Intismeran, jointly developed by Moderna and Merck Sharp & Dohme, was a success. It is the world's first mRNA cancer vaccine to have its Phase III data published, triggering a frenzy in the market (Moderna's stock price soared by 177%). However, this vaccine is not a "cure-all" for cancer: it is a therapeutic adjuvant vaccine designed for post-surgery patients with specific types of cancer (such as melanoma). It requires personalized customization and is expensive, so it will take some time before it becomes widely available. The technological highlight of this vaccine is the use of AI to assist in antigen design, which improves the efficiency of customization, but there is no need for excessive optimism.
Detailed Analysis
1. Not a “cure-all” for cancer – it only helps prevent recurrence
This vaccine is fundamentally different from the HPV vaccine: HPV is a preventive vaccine (given to people without cancer to prevent infection), while this is a therapeutic vaccine (used after a cancer diagnosis). Its purpose is not to cure cancer but to help reduce the risk of recurrence. For example, Phase IIb data show that when used in combination with the drug K, it can reduce the risk of recurrence or death in melanoma patients by 49%. Healthy individuals will not benefit from this vaccine, and expecting it to eliminate cancer is unrealistic. Even for cancer patients, it cannot be used directly; it must be used as an adjunct after primary treatments such as surgery, radiotherapy, and chemotherapy.
2. Not suitable for all cancers – limited application and high barriers
- Targeted at specific cancers: The trial focused on melanoma, which is common in Europe and the United States but has an incidence rate of only 0.4-1.3 per 100,000 in China, much lower than in those regions. Common cancers in China, such as lung and stomach cancer, do not currently have corresponding mRNA vaccines, so patients will have to wait.
- Personalized and expensive: This is a “custom-made” vaccine. The patient's cancer cells and healthy cells must be sequenced to identify mutations, and then a custom vaccine is designed. Similar to CAR-T therapy, which costs millions of dollars, this vaccine will likely be expensive and unaffordable for most families.
- Strict usage requirements: It is only for post-surgery patients and must be used in combination with the drug K; it cannot be used as a primary treatment for advanced stages of cancer.
3. Still a long way before it’s available to you
The success of Phase III does not mean the vaccine will be available immediately:
- These are only preliminary results; the full data will not be published until October 2029.
- Even if an application for market approval is submitted in 2026, the FDA’s fast-track process will take at least 6 months, and the regular approval process will take another year.
- After approval, patients still need to undergo sequencing and custom vaccine production, which will take at least another year, possibly longer.
4. AI plays a key role in customization
The core innovation of this vaccine lies in the use of AI to design antigens. The process is as follows:
1. Identify mutations: Sequencing of the patient's cancer cells and normal cells to identify unique mutations.
2. AI selects antigens: Using Moderna’s AI tool EchoNeo, 34 antigens that are most easily recognized by the immune system are selected from hundreds of potential candidates (traditional methods have a success rate of only 5%, while AI significantly improves this efficiency).
3. Vaccine production: The selected antigens are used to design the mRNA sequence, which is then packaged into nanoparticles to create the custom vaccine.
AI makes the customization process faster and more accurate, which is a trend in future cancer vaccines.
5. Market excitement should be measured – don’t let stock price fluctuations drive your decisions
On the day of the announcement, Moderna’s stock price surged by 177%, but it fell by 23% the following day, indicating that the market was initially overeager. While the technological breakthrough is exciting, it should be viewed rationally: this vaccine is an adjuvant treatment, not a miracle cure. Its application is limited, and its cost is high, so widespread use is still a long way off. Investors should not blindly follow the market, and healthcare professionals should not have unrealistic expectations.
In conclusion
This vaccine represents an important advancement in mRNA cancer therapy, but it is far from a solution to the problem of cancer. We should approach this technological development with a balanced perspective and avoid being influenced by emotional market reactions.
(Note: This article does not provide investment or medical advice.)